Eurofins-Cerep
Eurofins Cerep is a pharmacology testing service provider offering in vitro testing and biology research reagents.
- Public company
- Celle L'Evescault, FRFrance
Eurofins Cerep is a pharmacology testing service provider offering in vitro testing and biology research reagents.
Where is this company's market in its cycle, and what does that phase mean for it?
Eurofins Cerep's drug discovery sub-sector is in an early recovery following the 2025 contraction: the drug discovery market contracted in June 2025 before rising. That upturn lifted first-half 2026 revenue 18.22% to €21,552k, and operating income climbed to €3,650k from €1,042k a year earlier.
Eurofins Cerep expects revenue for the second half near the first-half level, and it continues to explore new applications around its biophysics platform.
What could change its growth trajectory, and what would confirm it?
A recovering drug discovery market after a June 2025 contraction and the momentum of new biophysics activities drove an 18.22% revenue increase for Eurofins-Cerep in the first half of 2026, lifting revenue to €21,552k from €18,231k a year earlier.
Eurofins-Cerep expects renewals of service contracts and new contracts for its biophysics and integrated drug discovery platforms to hold second-half revenue near the first-half level, while it continues exploring new biophysics applications and extends its collaboration with the University of Poitiers.
How does it make money per customer, and what is still unknown?
Because all of its revenue comes from service activities, Eurofins-Cerep's value capture can move only through service volume or service pricing. First-half 2026 revenue reached €21,552k, up from €18,231k a year earlier.
Operating income rose to €3,650k from €1,042k a year earlier, and net income reached €4,806k against €1,820k in the prior-year period. The company attributes the operating improvement to higher revenue combined with controlled expense growth.
What does the product do for its buyer, and how is it delivered?
Eurofins Cerep delivers in vitro pharmacology testing, screening and selectivity profiling services to pharmaceutical and biotechnology companies. The firm specialises in pharmacology services and conducts drug discovery research. It evaluates compound activity across many targets.
Mass spectrometry and biophysics platforms strengthen Eurofins Cerep's service offering. The company supports clients across early research phases.